Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer
International Journal of Urology · 2026
DOI: 10.1111/iju.70369 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Hidetsugu Takahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Tosyl Compounds, Anilides, Nitriles, Androgen Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate the real‐world effectiveness and safety of apalutamide versus bicalutamide in combination with androgen deprivation therapy (ADT) for metastatic hormone‐sensitive prostate cancer (mHSPC) in Japanese clinical practice.
Methods
This multicenter retrospective study analyzed 477 patients with mHSPC who received either apalutamide ( n = 102) or bicalutamide ( n = 375) in combination with ADT across 19 Japanese institutions. The primary outcome was time to castration‐resistant prostate cancer (CRPC). Secondary outcomes included overall survival (OS), prostate‐specific antigen (PSA) response, and adverse events.
Results
The apalutamide group showed significantly higher CRPC‐free probability at 24 months (68.2% vs. 39.8%, p < 0.001) compared to the bicalutamide group. While OS was similar between groups, the apalutamide group demonstrated superior PSA response at 3 months (median PSA: 0.8 vs. 3.4 ng/mL) and lower requirement for secondary treatment (36.3% vs. 53.9%, p = 0.002). Adverse events were more frequent in the apalutamide group (30.4% vs. 4.3%, p < 0.001), particularly rash (15.7% vs. 0.3%, p < 0.001).
Conclusions
In real‐world Japanese clinical practice, apalutamide demonstrated superior efficacy in delaying progression to CRPC compared to bicalutamide when combined with ADT for mHSPC, with manageable safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, The Jikei University West Medical Center, Tokyo, Japan.
- Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
ORCID-Profile: Hidetsugu Takahashi, Wataru Fukuokaya, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Kojiro Tashiro, Takahiro Kimura
Zitieren
APA
Takahashi, H., Fukuokaya, W., Muramoto, K., Katsumi, K., Urabe, F., Mori, K., Yanagisawa, T., Tashiro, K., Kimura, T., & JIKEI‐YAYOI Collaborative group (2026). Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70369
Vancouver
Takahashi H, Fukuokaya W, Muramoto K, Katsumi K, Urabe F, Mori K, et al. Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer. International Journal of Urology. 2026. doi:10.1111/iju.70369
BibTeX
@article{Takahashi2026,
author = {Takahashi, Hidetsugu and Fukuokaya, Wataru and Muramoto, Katsuki and Katsumi, Kota and Urabe, Fumihiko and Mori, Keiichiro and Yanagisawa, Takafumi and Tashiro, Kojiro and Kimura, Takahiro and JIKEI‐YAYOI Collaborative group, JIKEI‐YAYOI Collaborative group},
title = {Real‐World Comparative Study of Apalutamide Versus Bicalutamide in Combination With Androgen Deprivation Therapy for Metastatic Hormone‐Sensitive Prostate Cancer},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70369}
}
EUVIMED